BRPI0417225A - métodos de aumentar a resposta imune no compartimento intradérmico e compostos úteis nos referidos métodos - Google Patents

métodos de aumentar a resposta imune no compartimento intradérmico e compostos úteis nos referidos métodos

Info

Publication number
BRPI0417225A
BRPI0417225A BRPI0417225-6A BRPI0417225A BRPI0417225A BR PI0417225 A BRPI0417225 A BR PI0417225A BR PI0417225 A BRPI0417225 A BR PI0417225A BR PI0417225 A BRPI0417225 A BR PI0417225A
Authority
BR
Brazil
Prior art keywords
present
methods
antigenic
immunogenic
immune response
Prior art date
Application number
BRPI0417225-6A
Other languages
English (en)
Inventor
Robert Campbell
Kevin G Dolan
Jason Alarcon
Wendy D Woodley
John Mikszta
Original Assignee
Becton Dickinson Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton Dickinson Co filed Critical Becton Dickinson Co
Publication of BRPI0417225A publication Critical patent/BRPI0417225A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODOS DE AUMENTAR A RESPOSTA IMUNE NO COMPARTIMENTO INTRADéRMICO E COMPOSTOS úTEIS NOS REFERIDOS MéTODOS". A presente invenção se refere a composições imunogênicas para o envio intradérmico de um agente antigênico ou imunogênico em combinação com um ou mais excipientes. As composições imunogênicas da presente invenção compreendem um agente antigênico ou imunogênico e pelo menos um excipiente que atua como um adjuvante, isto é, aumenta a resposta imune ao agente antigênico ou imunogênico, uma vez enviado ao compartimento intradérmico da pele de um sujeito. As composições imunogênicas da presente invenção compreendem um excipiente o qual quando administrado ao compartimento intradérmico da pele de acordo com a presente invenção, demonstra atividade adjuvante. As composições imunogênicas da presente invenção apresentam eficácia aprimorada na medida em que os excipientes da composição provocam uma irritação na pele assintomática e recrutam as células que apresentam antígeno ao compartimento intradérmico, e assim, aumenta a apresentação e/ou disponibilidade do agente antigênico ou imunogênico as células que apresentam antígeno. A eficácia aprimorada das composições imunogênicas da presente invenção pode resultar em uma resposta imune terapeuticamente eficaz após uma única dose intradérmica, com menores doses de agente antigênico ou imunogênico do que as convenientemente usadas, e sem a necessidade de imunizações de reforço.
BRPI0417225-6A 2003-12-05 2004-12-06 métodos de aumentar a resposta imune no compartimento intradérmico e compostos úteis nos referidos métodos BRPI0417225A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52759903P 2003-12-05 2003-12-05
PCT/US2004/041021 WO2005074460A2 (en) 2003-12-05 2004-12-06 Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods

Publications (1)

Publication Number Publication Date
BRPI0417225A true BRPI0417225A (pt) 2007-03-06

Family

ID=34837337

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417225-6A BRPI0417225A (pt) 2003-12-05 2004-12-06 métodos de aumentar a resposta imune no compartimento intradérmico e compostos úteis nos referidos métodos

Country Status (8)

Country Link
US (2) US20050281832A1 (pt)
EP (1) EP1708742A4 (pt)
JP (1) JP2007516968A (pt)
CN (1) CN1905896A (pt)
AU (1) AU2004315509A1 (pt)
BR (1) BRPI0417225A (pt)
CA (1) CA2548210A1 (pt)
WO (1) WO2005074460A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
WO2006115509A2 (en) * 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
NZ567978A (en) * 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
SG10201508397VA (en) * 2007-04-06 2015-11-27 Takeda Vaccines Inc Methods and compositions for live attenuated viruses
AU2008352966C1 (en) * 2007-12-18 2014-09-25 Boston Medical Center Corporation Pre- or post-exposure treatment for filovirus or arenavirus infection
EA201000829A1 (ru) * 2007-12-21 2011-06-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
JP5588990B2 (ja) * 2008-10-31 2014-09-10 トレムアールエックス， インコーポレイテッド 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
JP5876468B2 (ja) 2011-02-25 2016-03-02 久光製薬株式会社 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
US9389229B2 (en) * 2012-07-18 2016-07-12 Theranos, Inc. Methods for detecting and measuring aggregation
EP3064218B1 (en) 2013-10-31 2019-06-19 Hisamitsu Pharmaceutical Co., Inc. Adjuvant composition
EP3113621B1 (en) * 2013-11-25 2020-10-28 Medline Industries, Inc., Catheter lock solution formulations
JP5917626B2 (ja) * 2014-07-28 2016-05-18 トレムアールエックス， インコーポレイテッド 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
EP3189854B1 (en) * 2014-09-03 2020-04-29 Nitto Denko Corporation Vaccine composition for transdermal or transmucosal administration
CN112379087B (zh) * 2020-10-21 2022-02-11 中国医学科学院医学生物学研究所 一种应用于新型冠状病毒灭活疫苗的裂解液及抗原解离的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0688911B2 (ja) * 1985-06-06 1994-11-09 国立予防衛生研究所長 インフルエンザワクチン及びその製造方法
NZ240369A (en) * 1990-10-30 1993-09-27 Daiichi Seiyaku Co Muramyl dipeptide derivatives and vaccine compositions
US6485729B1 (en) * 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
CA2172815A1 (en) * 1993-11-05 1995-05-11 Elizabeth J. Haanes Viral vector with bovine viral diarrhea virus (bvdv) antigens
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
US5861174A (en) * 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
US6734172B2 (en) * 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US6494865B1 (en) * 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
KR20020059719A (ko) * 1999-11-12 2002-07-13 추후보정 재조합 젤라틴
US20030170818A1 (en) * 2000-06-17 2003-09-11 Haley Dana A. Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides
EP1315672A4 (en) * 2000-06-22 2006-04-26 Rxkinetix Inc ADMINISTRATIVE COMPOSITION COMPOSITION AND METHOD FOR THE ADMINISTRATION OF ANTIGENES AND OTHER ACTIVE SUBSTANCES
US20040185055A1 (en) * 2001-03-19 2004-09-23 Glenn Gregory M Transcutaneous immunostimulation
US20030171253A1 (en) * 2001-04-19 2003-09-11 Averil Ma Methods and compositions relating to modulation of A20
AU2002254558A1 (en) * 2001-04-27 2002-11-11 Becton, Dickinson And Company Novel vaccine
US20030129161A1 (en) * 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
US7978710B2 (en) * 2004-03-26 2011-07-12 Qualcomm Incorporated Synchronous inter-piconet routing
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity

Also Published As

Publication number Publication date
WO2005074460A3 (en) 2005-09-29
EP1708742A2 (en) 2006-10-11
CA2548210A1 (en) 2005-08-18
AU2004315509A1 (en) 2005-08-18
JP2007516968A (ja) 2007-06-28
CN1905896A (zh) 2007-01-31
US20050281832A1 (en) 2005-12-22
EP1708742A4 (en) 2008-11-05
WO2005074460A9 (en) 2006-08-24
US20090304744A1 (en) 2009-12-10
WO2005074460A2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
BRPI0417225A (pt) métodos de aumentar a resposta imune no compartimento intradérmico e compostos úteis nos referidos métodos
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
BRPI0410249A (pt) moléculas que melhoram a distribuição dérmica de vacinas contra influenza
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
AR058543A1 (es) Nueva composicion de vacuna potenciada con un adyuvante liposomal
BR0111186A (pt) Uso de composição de celecoxib para rápido alìvio de dor
BRPI0510430A (pt) composições e métodos para vacinação mucosal
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
CR9348A (es) Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
ES2193159T3 (es) Una formulacion de factor de coagulacion viii.
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
BRPI0507895A (pt) composição para o tratamento de insuficiências venosas crÈnicas, compreendendo um extrato de folhas de videira-vermelha e um agente antiinflamatório
GT200500003A (es) Composicion farmaceutica apta para la compresion directa para la administracion oral de cci-779
BRPI0415713A (pt) mio-inositol hexafosfato para uso tópico
ECSP066685A (es) Composición que comprende un extracto acuoso de hojas de vid roja y un agente que mejora la circulación sanguínea para el tratamiento de insuficiencias venosas crónicas
BRPI0414500A (pt) formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
BR112023000730A2 (pt) Método para induzir e/ou ativar uma resposta imune, forma de dosagem, kit, vetor, célula hospedeira, partículas do vetor lentiviral pseudotipada e composição imunogênica
JP2017511327A5 (pt)
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
JP2020528452A (ja) 体臭の処置又は予防に用いるチロスリシン及びそのための製剤

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.